Abbott Reports Third-Quarter 2015 Results

ABBOTT PARK, Ill., Oct. 21, 2015 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2015.

• Third-quarter worldwide sales of $5.2 billion increased 10.9 percent on an operational basis and 1.4 percent on a reported basis.
• Adjusted diluted EPS from continuing operations, which excludes specified items, was $0.54 in the third quarter, at the high end of the previous guidance range. Reported diluted EPS from continuing operations under GAAP was $0.39.
• Abbott narrowed its full-year 2015 adjusted EPS guidance range for continuing operations to $2.14 to $2.16. Projected full-year 2015 EPS for continuing operations under GAAP is $1.59 to $1.61.
• Abbott achieved double-digit emerging market sales growth on an organic basis, which excludes the impact of 2014 acquisitions and foreign exchange.
• Abbott continues to deliver improvement in gross margin, while funding investments to expand its innovative product offerings and build new markets. In the third quarter, Abbott launched Similac^® Sensitive Non-GMO and Go & Grow by Similac^® Non-GMO in the U.S.; and continued the international rollout of its TECNIS^® Symfony Extended Range intraocular lens across multiple markets.

"Despite currency headwinds, we are on track to deliver the financial commitments we set at the beginning of the year," said Miles D. White, chairman and chief executive officer, Abbott.  "Our underlying growth is strong and we continue to see robust demand in emerging markets."

To read full press release, please click here.

Help employers find you! Check out all the jobs and post your resume.